TrialHaematologica2024

Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.

Emilio Iannitto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.